FI70793C - Foerfarande foer framstaellning av en stabil 4'-(9-akridinylamino)metansulfon -m-anisidin(m-amsa)-komposition - Google Patents

Foerfarande foer framstaellning av en stabil 4'-(9-akridinylamino)metansulfon -m-anisidin(m-amsa)-komposition Download PDF

Info

Publication number
FI70793C
FI70793C FI811474A FI811474A FI70793C FI 70793 C FI70793 C FI 70793C FI 811474 A FI811474 A FI 811474A FI 811474 A FI811474 A FI 811474A FI 70793 C FI70793 C FI 70793C
Authority
FI
Finland
Prior art keywords
amsa
lactic acid
water
solution
acridinylamino
Prior art date
Application number
FI811474A
Other languages
English (en)
Finnish (fi)
Other versions
FI70793B (fi
FI811474L (fi
Inventor
Murray Arthur Kaplan
Daniel Bouzard
Claude Perol
Jacques Stemer
Abraham Weber
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FI811474L publication Critical patent/FI811474L/fi
Publication of FI70793B publication Critical patent/FI70793B/fi
Application granted granted Critical
Publication of FI70793C publication Critical patent/FI70793C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI811474A 1980-05-16 1981-05-13 Foerfarande foer framstaellning av en stabil 4'-(9-akridinylamino)metansulfon -m-anisidin(m-amsa)-komposition FI70793C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14705680 1980-05-16
US06/147,056 US4360523A (en) 1980-05-16 1980-05-16 Pharmaceutical formulations of 4'-(9-acridinylamino)-methanesulfon-m-anisidide

Publications (3)

Publication Number Publication Date
FI811474L FI811474L (fi) 1981-11-17
FI70793B FI70793B (fi) 1986-07-18
FI70793C true FI70793C (fi) 1986-10-27

Family

ID=22520148

Family Applications (1)

Application Number Title Priority Date Filing Date
FI811474A FI70793C (fi) 1980-05-16 1981-05-13 Foerfarande foer framstaellning av en stabil 4'-(9-akridinylamino)metansulfon -m-anisidin(m-amsa)-komposition

Country Status (21)

Country Link
US (1) US4360523A (ja)
JP (1) JPS579716A (ja)
AT (1) AT374682B (ja)
AU (1) AU543726B2 (ja)
BE (1) BE888832A (ja)
CA (1) CA1160571A (ja)
CH (1) CH647677A5 (ja)
DE (1) DE3119510A1 (ja)
DK (1) DK159376C (ja)
FI (1) FI70793C (ja)
FR (1) FR2482458A1 (ja)
GB (1) GB2076288B (ja)
GR (1) GR75658B (ja)
IE (1) IE51285B1 (ja)
IT (1) IT1170970B (ja)
LU (1) LU83363A1 (ja)
NL (1) NL8102362A (ja)
NZ (1) NZ196985A (ja)
SE (1) SE460457B (ja)
YU (1) YU44831B (ja)
ZA (1) ZA813188B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575509A (en) * 1983-01-31 1986-03-11 Bristol-Myers Company Water-soluble formulations of m-AMSA with pyroglutamic acid
US4626541A (en) * 1985-09-12 1986-12-02 Bristol-Myers Company Water soluble salt composition of m-AMSA
DE3809814C1 (en) * 1988-03-23 1989-09-07 Karl Heinz Dr.Med. 7100 Heilbronn De Thiel Use of aminoacridines for iontophoretic treatment of bladder cancer
DE3819842C1 (ja) * 1988-03-23 1989-12-21 Karl Heinz Dr. 7100 Heilbronn De Thiel
CA2143515A1 (en) * 1994-03-22 1995-09-23 Prakash Parab Method for enhancing the rate of skin permeation of lactic acid through use of the l-enantiomer
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006002887A1 (en) * 2004-06-29 2006-01-12 Baxter International Inc. Aqueous drink solution of indibulin (d-24851) and an organic acid
CA2587276A1 (en) * 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor compounds
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
WO2015150383A1 (en) * 2014-03-31 2015-10-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Glycolic acid and/or d-lactic acid for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
IT1170970B (it) 1987-06-03
IE811092L (en) 1981-11-16
BE888832A (fr) 1981-11-16
DK159376C (da) 1991-03-25
FI70793B (fi) 1986-07-18
SE8103071L (sv) 1981-11-17
DE3119510A1 (de) 1982-02-25
JPH0136445B2 (ja) 1989-07-31
IE51285B1 (en) 1986-11-26
IT8148467A0 (it) 1981-05-14
GR75658B (ja) 1984-08-02
SE460457B (sv) 1989-10-16
CH647677A5 (de) 1985-02-15
LU83363A1 (fr) 1982-01-20
AU543726B2 (en) 1985-05-02
DK216681A (da) 1981-11-17
JPS579716A (en) 1982-01-19
NL8102362A (nl) 1981-12-16
CA1160571A (en) 1984-01-17
DE3119510C2 (ja) 1991-03-07
GB2076288B (en) 1983-12-14
NZ196985A (en) 1983-06-17
ZA813188B (en) 1982-05-26
ATA221181A (de) 1983-10-15
US4360523A (en) 1982-11-23
YU112381A (en) 1985-03-20
FR2482458A1 (fr) 1981-11-20
YU44831B (en) 1991-04-30
FI811474L (fi) 1981-11-17
AU7029181A (en) 1981-11-19
DK159376B (da) 1990-10-08
AT374682B (de) 1984-05-25
FR2482458B1 (ja) 1984-12-14
GB2076288A (en) 1981-12-02

Similar Documents

Publication Publication Date Title
US6987108B2 (en) Pharmaceutical formulations of antineoplastic agents and processes of making and using the same
US6780881B2 (en) Freeze-dried pantoprazole preparation and pantoprazole injection
FI109659B (fi) Levosimendaanin farmaseuttisia liuoksia
FI70793B (fi) Foerfarande foer framstaellning av en stabil 4'-(9-akridinylamino)metansulfon-m-anisidin(m-amsa)-komposition
CA1302278C (en) Injection solutions of torasemide which are ready to use and processes for their preparation thereof
US5942510A (en) Pharmaceutical composition containing lamotrigine
US5750131A (en) Ifosfamide lyophilizate preparations
US5681573A (en) Process to prepare pharmaceutical compositions containing vecuronium bromide and compositions produced thereby
US4425348A (en) Antitumor compositions
FI80023B (fi) Sammansaettningar, som verkar foerstoerande pao tumoerer.
JPH0343251B2 (ja)
US4322424A (en) Crystalline glucoconate salt of m-AMSA and compositions containing same
US4626541A (en) Water soluble salt composition of m-AMSA
US20080096947A1 (en) Parenteral Forms Of Administration Of Imexon And Method For The Production Thereof
CA1159368A (en) Antitumor compositions
AU2006235847C1 (en) Lyophilized pantoprazole preparation
JPH032862B2 (ja)
WIRKSTOFFEN et al. TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: BRISTOL-MYERS CO